Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Short Interest Update

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 1,558 shares, a decline of 38.3% from the December 15th total of 2,524 shares. Based on an average daily trading volume, of 3,750 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.1% of the shares of the stock are sold short. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 3,750 shares, the days-to-cover ratio is presently 0.4 days.

Fidelity Disruptive Medicine ETF Stock Performance

NASDAQ:FMED traded down $0.05 on Friday, hitting $27.47. 3,952 shares of the stock were exchanged, compared to its average volume of 9,823. Fidelity Disruptive Medicine ETF has a 52 week low of $20.69 and a 52 week high of $29.07. The stock has a market capitalization of $63.18 million, a price-to-earnings ratio of 41.33 and a beta of 1.00. The company’s 50-day moving average price is $27.62 and its 200 day moving average price is $25.72.

Institutional Investors Weigh In On Fidelity Disruptive Medicine ETF

An institutional investor recently raised its position in Fidelity Disruptive Medicine ETF stock. Wealth Enhancement Advisory Services LLC raised its holdings in Fidelity Disruptive Medicine ETF (NASDAQ:FMED) by 12.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 688,750 shares of the company’s stock after buying an additional 76,538 shares during the period. Wealth Enhancement Advisory Services LLC owned 31.31% of Fidelity Disruptive Medicine ETF worth $16,544,000 at the end of the most recent reporting period.

About Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.